Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2019
Reporting Period: The filing reports on an event occurring on January 26, 2019, regarding the commencement of a new investor presentation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation update and does not contain financial statements or performance data.
Material Changes
On January 26, 2019, the Company began utilizing a new presentation ("Investor Presentation") to convey information to prospective investors. This presentation is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the information provided, including the attached Investor Presentation, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that Section or the requirements of Item 10 of Regulation S-K.
Unusual Items: The filing explicitly notes that the furnishing of this information shall not be deemed an admission as to the materiality of any such information.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation) for specific operational updates or strategic shifts.
- Verify that the information in the presentation is not incorporated by reference into other SEC filings.
- Confirm the Company's status as an emerging growth company as indicated in the filing.